Decreased antibody response to influenza vaccine among nursing-home residents who received recalled vaccine--New York, 1996.
Following a voluntary recall in November 1996 of 11 lots of Fluogen trivalent influenza vaccine (Parke-Davis Division, Warner Lambert Company, Morris Plains, New Jersey), the New York State Department of Health and CDC evaluated antibody response to the 1996-97 influenza vaccine among residents (n = 86) of three nursing homes who received recalled vaccine and among residents (n = 86) of three other nursing homes who received vaccine produced by a different manufacturer. The Fluogen lots were recalled because the monitored quantity of A/Nanchang/933/95(H3N2) hemagglutinin antigen in the 1996-97 influenza vaccine had declined since the vaccine initially was released; the reason for this decrease is unknown. The findings of this analysis indicate that, compared with elderly nursing-home residents who received influenza vaccine from a different manufacturer, residents who received Fluogen from recalled lots had moderately lower antibody responses to the influenza A/Nanchang/933/95(H3N2) component of the 1996-97 influenza vaccine.
D000914:Antibodies, Viral / Q000096:biosynthesis* / Q000097:blood; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D009980:Influenza A virus / Q000276:immunology*; D009981:Influenza B virus / Q000276:immunology*; D007252:Influenza Vaccines / Q000276:immunology*; D009518:New York; D009735:Nursing Homes; D014611:Vaccination
D000914:Antibodies, Viral; D007252:Influenza Vaccines